Eliksa Therapeutics
2 known investors
Eliksa develops regenerative medicine therapies for rare diseases, processing acellular biological products in its own cGMP facility. Its lead investigational product, ELK-003, is an ophthalmic eye-drop drug targeting the ocular effects of Epidermolysis Bullosa, an ultra-rare genetic disorder affecting children.